Literature DB >> 2869727

Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs.

J A Cooper, D A White, R A Matthay.   

Abstract

Nonchemotherapeutic drugs may also cause pulmonary parenchymal alterations. Mechanisms of pulmonary damage by these agents are diverse and may involve alterations of pulmonary homeostasis. Clinical features of noncytotoxic, drug-induced pulmonary disease are more heterogeneous than those associated with cytotoxic drugs, and several clinical syndromes are equally represented. Treatment and outcome vary with each individual drug and clinical presentation. In part 2, clinical and pathogenic aspects of noncytotoxic, drug-induced pulmonary disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869727     DOI: 10.1164/arrd.1986.133.3.488

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  26 in total

Review 1.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

2.  Interstitial pneumonitis during lamotrigine therapy.

Authors:  Narayanamoorti Saravanan; Olayiwala Musibay Otaiku; Robert Namushi Namushi
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

3.  Giant cell interstitial pneumonia associated with nitrofurantoin.

Authors:  Charles William Hargett; Thomas A Sporn; Victor L Roggli; John W Hollingsworth
Journal:  Lung       Date:  2006 May-Jun       Impact factor: 2.584

4.  Technetium-99m hexamethylpropylene amine oxime lung scintigraphy findings in low-dose amiodarone therapy.

Authors:  G Capa Kaya; T Ertay; B Tuna; R Bekis; C Tasci; E Sayit; O Yilmaz; A Kargi; H Durak
Journal:  Lung       Date:  2006 Mar-Apr       Impact factor: 2.584

5.  Drug-associated acute lung injury: a population-based cohort study.

Authors:  Rajanigandha Dhokarh; Guangxi Li; Christopher N Schmickl; Rahul Kashyap; Jyoti Assudani; Andrew H Limper; Ognjen Gajic
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

6.  Severe pulmonary edema associated with tocolytic therapy. Case report with hemodynamic study.

Authors:  D Leduc; R Naeije; M Leeman; C Homans; R J Kahn
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

7.  Irreversible interstitial pneumonitis associated with tocainide therapy.

Authors:  B Van Natta; M Lazarus; C Li
Journal:  West J Med       Date:  1988-07

8.  Extensive pneumothorax, pneumomediastinum and surgical emphysema as a complication of bleomycin therapy.

Authors:  Tarun P Jain; Sanjay Thulkar; Sanchita Saha; Sameer Bakhshi; Joseph Dominic
Journal:  Pediatr Radiol       Date:  2005-08-12

9.  Circulating KL-6 levels in patients with drug induced pneumonitis.

Authors:  H Ohnishi; A Yokoyama; Y Yasuhara; A Watanabe; T Naka; H Hamada; M Abe; K Nishimura; J Higaki; J Ikezoe; N Kohno
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

10.  Diphenylhydantoin (phenytoin)-induced chronic pulmonary disease.

Authors:  Ramakant Dixit; Kalpana Dixit; Paras Nuwal; Arunima Banerjee; Sidharth Sharma; Lokendra Dave
Journal:  Lung India       Date:  2009-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.